Paloma Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Paloma Partners’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-22,026	Closed	-$143K	–	1493
2019 Q4	$143K	Sell	22,026 -20,806	-49%	-$112K	﹤0.01%	2018
2019 Q3	$206K	Sell	42,832 -11,568	-21%	-$51.1K	﹤0.01%	1738
2019 Q2	$218K	Buy	+54,400	New	+$230K	﹤0.01%	1497

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Paloma Partners's FENC Position: Q1 2020 in Review

Paloma Partners sold out of Fennec Pharmaceuticals (FENC) in Q1 2020, closing a stake of 22,026 shares — an estimated $143K sold.

Paloma Partners first reported a position in FENC in Q2 2019 and held it in 3 quarters. The position peaked at $218K in Q2 2019. 29 funds tracked by Wall St. Rank hold FENC as of Q1 2020.

Paloma Partners reported no remaining Fennec Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 22,026 Fennec Pharmaceuticals shares in Q1 2020, an estimated $143K.
Paloma Partners first reported a position in Fennec Pharmaceuticals in Q2 2019 and held it in 3 quarters.
Paloma Partners's Fennec Pharmaceuticals position peaked at $218K in Q2 2019.
29 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.